Negotiating Dedicated Bioreactor Capacity with Global CDMO Manufacturers
CDMO viral vector capacity is constrained globally. Here is how clinical-stage biotechs secure guaranteed manufacturing slots without punitive take-or-pay penalties.
Vishal VermaCTO & Co-Founder, Dehurdle
March 02, 20234 min read
The CDMO Capacity Reservation Script
Recommended Spoken Script
"We are reserving two 500L viral vector bioreactor suites for Q3 clinical manufacturing. In exchange for a 2-year rolling production commitment with a $2M deposit, we require a flexible 60-day slot deferral window without take-or-pay penalties if clinical trial patient dosing experiences schedule shifts."
The 2-Minute Practice Drill
2-Minute Spoken Drill
The 2-Minute Practice Drill
Practice CDMO contract negotiations in Dehurdle.